Gen­fit's elafi­bra­nor wins or­phan sta­tus for pri­ma­ry bil­iary cholan­gi­tis; Cidara stock soars on pos­i­tive an­ti-fun­gal mid-stage da­ta

→ NASH hope­ful Gen­fit has been award­ed or­phan drug sta­tus by US and EU reg­u­la­tors for its ex­per­i­men­tal drug, elafi­bra­nor, to treat pa­tients with pri­ma­ry bil­iary cholan­gi­tis (PBC), a chron­ic dis­ease in which bile ducts in the liv­er are grad­u­al­ly de­stroyed. The PPAR dual ag­o­nist, which is in a piv­otal tri­al in­volv­ing NASH pa­tients,  is cur­rent­ly in mid-stage de­vel­op­ment for PBC. The French drug de­vel­op­er $GN­FT re­cent­ly made its Nas­daq de­but, and last month inked up to $228 mil­lion deal with transpa­cif­ic biotech Terns Phar­ma­ceu­ti­cals to de­vel­op the liv­er drug in Greater Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER